Novartis has secured FDA approval for its Beovu (brolucizumab) injection in the treatment of wet age-related macular degeneration (AMD), it has emerged.
The decision makes it the first anti-VEGF drug approved by the FDA to “maintain eligible wet AMD patients on a three-month dosing interval immediately after a three-month loading phase with uncompromised efficacy”, while also offering greater fluid resolution compared to Regeneron’s Eylea (aflibercept).
